Acumen Pharmaceuticals (ABOS) vs Cardiol Therapeutics (CRDL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cardiol Therapeutics (CRDL) has outperformed Acumen Pharmaceuticals (ABOS) over the past year, gaining 24.5% versus a gain of 11.7%. Over five years, CRDL leads with a -66.4% price change compared with -84.5% for ABOS. Cardiol Therapeutics is the larger company by market cap ($160.4 million vs $151.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABOS | CRDL |
|---|---|---|
| Share price | $2.10 | $1.32 |
| Market cap | $151.87M | $160.40M |
| 1-day change | +3.45% | +0.76% |
| YTD return | -0.47% | +38.36% |
| 1-year return | +11.70% | +24.53% |
| 5-year return | -84.50% | -66.41% |
| EPS (TTM) | $-1.64 | $-0.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.60 | $2.34 |
| 52-week low | $1.50 | $0.88 |
| Distance from 52-week high | -41.67% | -43.59% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +261.90% | +533.33% |
| Average volume | 432.46K | 1.39M |
| Shares outstanding | 72.32M | 121.51M |
| Employees | 60 | 18 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDL has outperformed ABOS by 12.8 percentage points over the past year.
About Acumen Pharmaceuticals
ABOS stock →Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Healthcare · Biotechnology · 60 employees
About Cardiol Therapeutics
CRDL stock →Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Healthcare · Drug Manufacturers - Specialty & Generic · 18 employees
ABOS vs CRDL FAQ
Which is bigger, Acumen Pharmaceuticals or Cardiol Therapeutics?
Cardiol Therapeutics (CRDL) is larger, with a market capitalization of $160.40M compared with $151.87M for Acumen Pharmaceuticals (ABOS).
Which stock has performed better over the past year, ABOS or CRDL?
CRDL returned +24.53% over the past 12 months, compared with +11.70% for ABOS (price return, excluding dividends). Past performance does not predict future results.
Are Acumen Pharmaceuticals and Cardiol Therapeutics in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Acumen Pharmaceuticals and Drug Manufacturers - Specialty & Generic for Cardiol Therapeutics.